DE60035356D1 - Faktor ix/faktor ixa aktivierende antikörper - Google Patents
Faktor ix/faktor ixa aktivierende antikörperInfo
- Publication number
- DE60035356D1 DE60035356D1 DE60035356T DE60035356T DE60035356D1 DE 60035356 D1 DE60035356 D1 DE 60035356D1 DE 60035356 T DE60035356 T DE 60035356T DE 60035356 T DE60035356 T DE 60035356T DE 60035356 D1 DE60035356 D1 DE 60035356D1
- Authority
- DE
- Germany
- Prior art keywords
- factor
- activating antibodies
- ixa activating
- ixa
- fixa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0157699A AT411997B (de) | 1999-09-14 | 1999-09-14 | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
AT157699 | 1999-09-14 | ||
PCT/EP2000/008936 WO2001019992A2 (en) | 1999-09-14 | 2000-09-13 | FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60035356D1 true DE60035356D1 (de) | 2007-08-09 |
DE60035356T2 DE60035356T2 (de) | 2008-02-14 |
Family
ID=3516408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60035356T Expired - Lifetime DE60035356T2 (de) | 1999-09-14 | 2000-09-13 | Faktor ix/faktor ixa aktivierende antikörper |
Country Status (15)
Country | Link |
---|---|
US (2) | US7033590B1 (de) |
EP (1) | EP1220923B1 (de) |
JP (2) | JP4313531B2 (de) |
CN (1) | CN1390258A (de) |
AT (2) | AT411997B (de) |
AU (1) | AU780775B2 (de) |
CA (1) | CA2384660A1 (de) |
CZ (1) | CZ2002935A3 (de) |
DE (1) | DE60035356T2 (de) |
ES (1) | ES2288873T3 (de) |
HU (1) | HUP0203750A3 (de) |
PL (1) | PL354976A1 (de) |
RU (1) | RU2002109586A (de) |
SK (1) | SK3662002A3 (de) |
WO (1) | WO2001019992A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
JP5438880B2 (ja) * | 2003-10-10 | 2014-03-12 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US20080075712A1 (en) * | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
SI1876236T1 (sl) * | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
EP1760092A1 (de) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System für Screening von Zellen mit hoher Expression von einem interessierenden Protein |
CN101479381B (zh) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
EP2101816B1 (de) | 2006-12-07 | 2013-08-14 | Novartis AG | Antagonistische antikörper gegen ephb3 |
CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
EP2915564B1 (de) * | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Gegenmittel für Faktor-XA-Hemmer und Verfahren zur Verwendung davon |
AR071478A1 (es) | 2008-04-17 | 2010-06-23 | Baxter Healthcare Sa | Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi |
WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
JP2009292822A (ja) * | 2009-07-23 | 2009-12-17 | Chugai Pharmaceut Co Ltd | 機能蛋白質を代替する二種特異性抗体 |
WO2011080322A1 (en) | 2009-12-30 | 2011-07-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia |
WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子 |
AU2012267484B2 (en) | 2011-06-10 | 2017-03-23 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
PL220297B1 (pl) * | 2012-11-07 | 2015-10-30 | Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności& | Epitop i jego zastosowanie |
PT3050896T (pt) | 2013-09-27 | 2021-08-24 | Chugai Pharmaceutical Co Ltd | Processo para a produção de heteromultímeros de polipéptidos |
EP3065769A4 (de) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Prokoagulatorische fusionsverbindung |
WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
WO2016160622A2 (en) * | 2015-03-27 | 2016-10-06 | University Of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
EP3273994B1 (de) | 2015-03-27 | 2021-12-01 | University of Southern California | Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
CA3004288A1 (en) | 2015-12-28 | 2017-07-06 | Nobuyuki Tanaka | Method for promoting efficiency of purification of fc region-containing polypeptide |
KR102481704B1 (ko) | 2016-05-16 | 2022-12-27 | 다케다 파머수티컬 컴패니 리미티드 | 항-인자 ix 파두아 항체 |
TWI786061B (zh) | 2016-09-06 | 2022-12-11 | 日商中外製藥股份有限公司 | 使用辨識凝血因子ix及/或活化的凝血因子ix以及凝血因子x及/或活化的凝血因子x之雙特異性抗體之方法 |
CN110023339A (zh) * | 2016-09-23 | 2019-07-16 | Csl有限公司 | 凝血因子结合蛋白及其应用 |
JP7227146B2 (ja) * | 2016-11-23 | 2023-02-21 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固第ix因子および凝固第x因子に結合する二重特異性抗体 |
US20210388114A1 (en) | 2017-02-01 | 2021-12-16 | Novo Nordisk A/S | Procoagulant Antibodies |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
CN111902427A (zh) * | 2017-11-22 | 2020-11-06 | 诺华股份有限公司 | 抗因子XI/XIa抗体的逆转结合剂及其用途 |
CN109837303A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
CN109836496A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
CN117384296A (zh) | 2018-08-01 | 2024-01-12 | 诺和诺德股份有限公司 | 改进的促凝血抗体 |
TWI772724B (zh) | 2018-12-21 | 2022-08-01 | 英商克馬伯有限公司 | 具有共同輕鏈的FIXaxFX雙專一性抗體 |
JP2023512089A (ja) | 2020-01-30 | 2023-03-23 | ノヴォ ノルディスク アー/エス | 二重特異性第viii因子模倣抗体 |
CN116333145B (zh) * | 2023-04-14 | 2023-11-07 | 北京基科晟斯医药科技有限公司 | 结合活化凝血因子ix的抗体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JP3735112B2 (ja) * | 1992-08-27 | 2006-01-18 | ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス | 凝血性蛋白質に特異的な抗体、未変性蛋白質を単離するためのそれらの利用、その蛋白質の蛋白質分解性開裂産物を含まない凝血性組成物 |
DK128093D0 (da) * | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
EP1001991A4 (de) * | 1997-07-03 | 2005-01-26 | Smithkline Beecham Corp | KRISTALLINE STRUKTUREN DER ANTI-FAKTOR IX Fab FRAGMENTE SOWIE VERWENDUNGSVERFAHREN ZUM PEPTIDOMIMETISCHEN DESIGN |
ATE217889T1 (de) * | 1998-08-28 | 2002-06-15 | Genentech Inc | Humane antikörper gegen faktor ix/ixa |
AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
-
1999
- 1999-09-14 AT AT0157699A patent/AT411997B/de not_active IP Right Cessation
-
2000
- 2000-09-13 PL PL00354976A patent/PL354976A1/xx not_active Application Discontinuation
- 2000-09-13 DE DE60035356T patent/DE60035356T2/de not_active Expired - Lifetime
- 2000-09-13 RU RU2002109586/13A patent/RU2002109586A/ru not_active Application Discontinuation
- 2000-09-13 AU AU77759/00A patent/AU780775B2/en not_active Expired
- 2000-09-13 CN CN00815678A patent/CN1390258A/zh active Pending
- 2000-09-13 EP EP00967666A patent/EP1220923B1/de not_active Expired - Lifetime
- 2000-09-13 HU HU0203750A patent/HUP0203750A3/hu unknown
- 2000-09-13 ES ES00967666T patent/ES2288873T3/es not_active Expired - Lifetime
- 2000-09-13 SK SK366-2002A patent/SK3662002A3/sk unknown
- 2000-09-13 CZ CZ2002935A patent/CZ2002935A3/cs unknown
- 2000-09-13 WO PCT/EP2000/008936 patent/WO2001019992A2/en active IP Right Grant
- 2000-09-13 JP JP2001523763A patent/JP4313531B2/ja not_active Expired - Lifetime
- 2000-09-13 CA CA002384660A patent/CA2384660A1/en not_active Abandoned
- 2000-09-13 AT AT00967666T patent/ATE365799T1/de not_active IP Right Cessation
- 2000-09-14 US US09/661,992 patent/US7033590B1/en not_active Expired - Lifetime
-
2005
- 2005-03-28 US US11/093,103 patent/US7279161B2/en not_active Expired - Lifetime
- 2005-12-28 JP JP2005380504A patent/JP2006111638A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU7775900A (en) | 2001-04-17 |
US20050196397A1 (en) | 2005-09-08 |
ES2288873T3 (es) | 2008-02-01 |
SK3662002A3 (en) | 2002-07-02 |
EP1220923B1 (de) | 2007-06-27 |
WO2001019992A3 (en) | 2001-09-27 |
HUP0203750A2 (hu) | 2003-02-28 |
JP2006111638A (ja) | 2006-04-27 |
AU780775B2 (en) | 2005-04-14 |
WO2001019992A2 (en) | 2001-03-22 |
JP2003509049A (ja) | 2003-03-11 |
US7033590B1 (en) | 2006-04-25 |
RU2002109586A (ru) | 2004-03-10 |
CN1390258A (zh) | 2003-01-08 |
JP4313531B2 (ja) | 2009-08-12 |
ATA157699A (de) | 2004-01-15 |
PL354976A1 (en) | 2004-03-22 |
ATE365799T1 (de) | 2007-07-15 |
CA2384660A1 (en) | 2001-03-22 |
AT411997B (de) | 2004-08-26 |
DE60035356T2 (de) | 2008-02-14 |
US7279161B2 (en) | 2007-10-09 |
EP1220923A2 (de) | 2002-07-10 |
CZ2002935A3 (cs) | 2002-08-14 |
HUP0203750A3 (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60035356D1 (de) | Faktor ix/faktor ixa aktivierende antikörper | |
DK1187632T3 (da) | Behandling med anti-ErbB2-antistoffer | |
CY1117551T1 (el) | Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου | |
DK1189634T3 (da) | Behandling af prostatacancer med anti-ErbB2-antistoffer | |
IS6195A (is) | Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki | |
CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
DE60035032D1 (de) | Verwendung von pioglitazone zur verbesserung der ketose und der azidose | |
TR200103575T2 (tr) | Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler | |
TR200101906T2 (tr) | Antiviral ajanlar olarak kuinolinkarboksamitler | |
DE69924386D1 (de) | Sofortige Nachrichtenübermittlung | |
ATE304358T1 (de) | (s,s)-reboxetin zur behandlung von migränekopfschmerzen | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
ATE299139T1 (de) | Ccr5 antagonisten verwendbar für die behandlung von aids | |
NO20044898L (no) | Nye etonogestrel estere | |
DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
DE69901569T2 (de) | Humane antikörper gegen faktor ix/ixa | |
TR200103119T2 (tr) | Göz kurumasının tedavisi için madde. | |
TR200102448T2 (tr) | COPD tedavisi için kontrollu salma formülasyonu. | |
ITMI20021729A1 (it) | Apparecchio emanatore per l'emanazione di soluzioni. | |
ITRM990426A0 (it) | Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi. | |
ES2133634T3 (es) | Sistemas catalizadores metalocenicos portados. | |
DK1223930T3 (da) | Behandling af dyskinesi | |
ATE277924T1 (de) | Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression | |
IT1306193B1 (it) | Uso degli ultrasuoni per il trattamento della sintomatologia dadecompressione. | |
DE69937145D1 (de) | Klangquelle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |